Cutera マネジメント

マネジメント基準チェック /04

Cuteraの CEO はTaylor Harrisで、 Aug2023年に任命され、の在任期間は 1.25年です。の年間総報酬は$ 7.69Mで、 3.5%給与と96.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.44%を直接所有しており、その価値は€ 26.83K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と1.5年です。

主要情報

Taylor Harris

最高経営責任者

US$7.7m

報酬総額

CEO給与比率	3.5%
CEO在任期間	1.3yrs
CEOの所有権	0.4%
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	1.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Cutera の収益と比較して、Taylor Harris の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$144m
Jun 30 2024	n/a	n/a	-US$149m
Mar 31 2024	n/a	n/a	-US$158m
Dec 31 2023	US$8m	US$271k	-US$163m

報酬と市場: Taylorの総報酬 ($USD 7.69M ) は、 German市場 ($USD 471.55K ) の同規模の企業の平均を上回っています。

報酬と収益: Taylorの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Taylor Harris (48 yo)

1.3yrs

在職期間

US$7,685,535

報酬

Mr. Taylor C. Harris serves as Director of Omada Health, Inc. since February 2022. He serves as Advisor at Lauxera Capital Partners. Mr. Harris has been an Independent Director at HealthCor Catalio Acquisi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Taylor Harris	President	1.3yrs	US$7.69m	0.44% € 26.8k
Stuart Drummond	Chief Financial Officer	1.5yrs	US$777.83k	0.088% € 5.4k
Jeffrey Jones	Chief Operating Officer	1.3yrs	US$541.00k	データなし
Stephana Patton	Chief Legal Officer	less than a year	US$347.73k	0.020% € 1.2k
Charles Thier	Chief Information Officer	5.1yrs	US$1.86m	データなし
Greg Barker	Vice President of FP&A and Investor Relations	no data	データなし	データなし
Steve Kreider	Senior Vice President of Global Marketing	2.8yrs	データなし	データなし
Brent Hauser	President of International	1.1yrs	データなし	データなし
Shelby Eckerman	Vice President of Finance	no data	データなし	データなし

1.3yrs

平均在職期間

55.5yo

平均年齢

経験豊富な経営陣: TJ9の経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Taylor Harris	President	1.5yrs	US$7.69m	0.44% € 26.8k
Jeryl Hilleman	Director	less than a year	データなし	データなし
Kevin Cameron	Independent Chairman	1.5yrs	US$285.40k	データなし
Keith Sullivan	Independent Director	1.5yrs	US$220.05k	0.020% € 1.2k
Nicholas Lewin	Independent Director	1.5yrs	US$268.79k	データなし

1.5yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: TJ9の取締役会は経験豊富ではない ( 1.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Cutera マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

High number of new and inexperienced directors

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

High number of new and inexperienced directors

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

Recent updates

Cutera Receives Deficiency Notice from Nasdaq Regarding Minimum $15 Million Market Value of Publicly Held Shares Requirement under Nasdaq Marketplace Rule 5450(b)(3)(C)

New major risk - Market cap size

Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024

Cutera, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1)

Second quarter 2024 earnings released: US$1.23 loss per share (vs US$1.68 loss in 2Q 2023)

Cutera, Inc. Revises Revenue Guidance for the Year 2024

High number of new and inexperienced directors

Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cutera, Inc.(NasdaqGS:CUTR) dropped from Russell 3000 Index

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

Cutera, Inc. Reiterates Earnings Guidance for 2024

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$2.22 loss per share (vs US$0.62 loss in 3Q 2022)

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought €274k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Second quarter 2023 earnings released: US$1.59 loss per share (vs US$2.53 loss in 2Q 2022)

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$1.27 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$4.39 loss per share (vs US$0.12 profit in FY 2021)

Now 26% undervalued after recent price drop

Full year 2022 earnings released: US$4.39 loss per share (vs US$0.12 profit in FY 2021)

Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.077 loss in 3Q 2021)

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Cutera, Inc. Announces Committee Appointments

Cutera, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Cutera, Inc. Announces Resignation of Katherine S. Zanotti from the Board

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$2.53 loss per share (vs US$0.43 profit in 2Q 2021)

Cutera, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cutera, Inc. Announces AviClear Secured Clearance from Health Canada

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.02 loss in 1Q 2021)

Cutera, Inc., Annual General Meeting, Jun 15, 2022

Cutera Announces First Patient Treated with FDA Cleared Aviclear Acne Device

High number of new directors

CEO & Director recently bought €92k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cutera, Inc. Provides Revenue Guidance for the Year 2022

マネジメント基準チェック /04